P341 Clinical Characteristics and Outcomes of Crohn’s Disease with Upper Gastrointestinal Involvement: A Comprehensive Retrospective Cohort Study
W C Hsu,P H Le,C J Kuo,P J Yeh,M W Lai,R C Wu,C M Chen,C T Chiu,M Y Su,Y B Pan
DOI: https://doi.org/10.1093/ecco-jcc/jjad212.0471
2024-01-01
Journal of Crohn's and Colitis
Abstract:Abstract Background Crohn's Disease (CD) affects the entire gastrointestinal tract, predominantly involving the terminal ileum and colon. However, the incidence and implications of upper gastrointestinal tract involvement in CD are often underestimated and underreported, especially in Asian populations. This study provides a comprehensive evaluation of the clinical characteristics and outcomes associated with UGI involvement in CD. Methods We conducted a retrospective cohort study at Chang Gung Memorial Hospital, Linkou, from January 2001 to June 2023, including CD patients with consistent follow-up records. Patients were categorized into two groups based on UGI involvement: Montreal L4 and non-L4. Comparative analyses were performed between the groups regarding baseline characteristics, new-onset complications post L4 disease diagnosis, and clinical outcomes. Results The study included 223 CD patients, 114 in the L4 group and 109 in the non-L4 group, with an average follow-up of 40.6 months. Initially, the L4 group showed higher smoking prevalence (21.1% vs. 5.5%, P<0.001), higher Crohn’s Disease Activity Index (CDAI) scores (302.6±85.6 vs. 272.8±106.3, P=0.023), increased stricture disease (Montreal B2) incidence (55% vs. 48.2%, P<0.001), and more frequent use of biologics (12.3% vs.3.7%, P=0.021) and proton pump inhibitors (64.9% vs. 52%, P=0.014). They also had lower albumin levels (3.6±0.8 vs. 3.9±0.7, P=0.011) and reduced peri-anal (14.9% vs. 26.8%, P=0.026) and fistulizing disease incidences (14% vs. 26.6%, P=0.016). At follow-up end, the L4 group continued to exhibit higher CDAI scores (153.6±98.7 vs. 114.4±71.8, P = 0.001), increased hospitalization rates (0.6±1.1 vs. 0.3±0.5 times/year, P=0.009), elevated C-reactive protein levels (15.2±37.8 vs. 6.9±15.1, P=0.036), and decreased albumin levels (4±0.7 vs. 4.2±0.4, P=0.018). Though they had a lower incidence of new-onset perianal fistula (6.7% vs. 3.7%, P=0.041), the L4 group had higher incidences of most new-onset CD-related complications, including strictures (44% vs. 20.2%, P<0.001), enter enteral fistulae (11.9% vs. 3.5%, P=0.036), and intraabdominal abscesses (17.4% vs. 5.3%, P=0.009). Conclusion CD with UGI involvement is associated with higher disease activity and an increased risk of IBD-related complications. Comprehensive assessments at diagnosis and aggressive treatments are crucial for these patients to mitigate poorer outcomes.
gastroenterology & hepatology